Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

InflammamiRs profile in myelodysplastic syndrome patients

Version 1 : Received: 26 February 2024 / Approved: 26 February 2024 / Online: 27 February 2024 (10:12:07 CET)

How to cite: Montes, P.; Rusanova, I.; Cornejo, E.; García, P.; Guerra-Librero, A.; López, M.D.S.; Haro, T.D.; Escames, G.; Acuña-Castroviejo, D. InflammamiRs profile in myelodysplastic syndrome patients. Preprints 2024, 2024021510. https://doi.org/10.20944/preprints202402.1510.v1 Montes, P.; Rusanova, I.; Cornejo, E.; García, P.; Guerra-Librero, A.; López, M.D.S.; Haro, T.D.; Escames, G.; Acuña-Castroviejo, D. InflammamiRs profile in myelodysplastic syndrome patients. Preprints 2024, 2024021510. https://doi.org/10.20944/preprints202402.1510.v1

Abstract

Etiological factors involved in myelodysplastic syndrome (MDS) include immunologic, oxidative stress, and inflammatory factors, among others, and these are targets for microRNAs (miRNs). Here, we evaluated whether some miRNs may affect the tumor development comparing untreated and 5-azacitidine (5-AZA) MDS-treated patients. Peripheral blood samples were collected from 20 controls and 24 MDS patients, and selected miRNs related to redox balance and inflammation, including miR-18a, miR-21, miR-34a and miR-146a, were isolated and measured by quantitative real-time polymerase chain reaction (qRTPCR). A differential expression profile of miRNs was detected in untreated MDS patients and 5-AZA group. MiR-18a, miR-21, miR-34a and miR-146a were significantly overexpressed in untreated MDS, compared to controls. However, we did not observe any miRNs profile alteration during the progression of the disease. On the other hand, 5-AZA treatment tends to restore miRNs expression levels. Relating to prognostic risk factors, high risk MDS groups (high IPSS-R, high cytogenetic risk, high molecular risk (HMR) mutations tended to be related with higher expression levels of miR-18a and miR-34a. Higher miRNs expression is correlated with lower glutathione peroxidase activity, while they are related with a higher profile of pro-inflammatory cytokines (IL-2, IL-6, IL-8, TNF-α). Although our study was limited by the low number of MDS patients included, we identified miRNs deregulation involved in the MDS development, that could regulate redox sensors and inflammatory responses. Finally, 5-AZA treatment is related with lower miRNs expression levels in MDS patients.

Keywords

myelodysplastic syndrome (MDS); microRNAs (miRNs); oxidative stress; inflammatory cytokines; 5-azacitidine (5-AZA)

Subject

Medicine and Pharmacology, Pediatrics, Perinatology and Child Health

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.